Get the Stockscreener App
22.74
1.09%
-0.25
Pre-market:
22.76
0.02
+0.09%
Pacira Biosciences Inc stock is traded at $22.74, with a volume of 349.38K.
It is down -1.09% in the last 24 hours and up +0.44% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$22.99
Open:
$23.05
24h Volume:
349.38K
Relative Volume:
0.62
Market Cap:
$894.77M
Revenue:
$734.86M
Net Income/Loss:
$5.14M
P/E Ratio:
181.92
EPS:
0.125
Net Cash Flow:
$132.71M
1W Performance:
-0.52%
1M Performance:
+0.44%
6M Performance:
-14.77%
1Y Performance:
-6.19%
1-Day Range:
$22.59
$23.13
1-Week Range:
$22.59
$24.03
52-Week Range:
$18.80
$27.64
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.74 | 894.77M | 734.86M | 5.14M | 132.71M | 0.125 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Nov-17-25 | Initiated | H.C. Wainwright | Buy |
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight - GlobeNewswire Inc.
Insider Sell: Lauren Riker Sells Shares of Pacira BioSciences In - GuruFocus
Pacira BioSciences SVP Lauren Riker sells $143,702 in stock By Investing.com - Investing.com India
Pacira BioSciences SVP Lauren Riker sells $143,702 in stock - Investing.com
Pacira BioSciences (PCRX) director receives RSU and stock option grants - Stock Titan
Pacira (PCRX) director Mark Froimson receives new stock and option grants - Stock Titan
PCRX (NASDAQ) shows 2,876 and 6,163 restricted shares vesting - Stock Titan
Pacira BioSciences Announces Election of All Director Nominees at 2026 Annual Meeting and Highlights Non-Opioid Pain Therapies Strategy – Minichart - Minichart
Pacira BioSciences (NASDAQ:PCRX) Stock Crosses Below 50 Day Moving AverageShould You Sell? - MarketBeat
Pacira (NASDAQ: PCRX) investors reelect board nominees and add 800,000 ESPP shares - Stock Titan
[144] Pacira BioSciences, Inc. SEC Filing - Stock Titan
Biotech company shareholders elect Chris Christie in rejecting activist investor's slate - The Business Journals
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting - Yahoo Finance
Pacira BioSciences (PCRX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Pacira shareholders lobbied by hedge fund board nominees - MSN
Pacira BioSciences CAO Kristen Williams sells $228,467 in stock By Investing.com - Investing.com Australia
Technical Reactions to PCRX Trends in Macro Strategies - Stock Traders Daily
Pacira BioSciences CAO Kristen Williams sells $228,467 in stock - Investing.com
Pacira (PCRX) SVP has 3,187 shares withheld for tax obligations - Stock Titan
Pacira BioSciences (NASDAQ: PCRX) CMO has 4,728 shares withheld for taxes - Stock Titan
Pacira (PCRX) CAO sells 10,259 shares under pre-set 10b5-1 trading plan - Stock Titan
Three major proxy firms side with Pacira in boardroom showdown - Stock Titan
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting - Yahoo Finance
Pacira Stock Waits for June 9 Board Fight - Bez Kabli
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release - AOL.com
PCRX DEADLINE NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class ActionPCRX - TMX Newsfile
Pacira Biosciences Inc (NASDAQ:PCRX) Emerges as a Deep Value Opportunity with Strong Financial Health - ChartMill
Press Release: Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees - Moomoo
Pacira BioSciences, Inc.Common Stock (NQ: PCRX - FinancialContent
Pacira (PCRX): Glass Lewis Recommends Stockholder Votes - GuruFocus
Glass Lewis Backs Pacira BioSciences Director Slate Ahead of Key VoteRevenue Guidance Update - The Legal Advocate
[DFAN14A] Pacira BioSciences, Inc. SEC Filing - Stock Titan
Pacira Biosciences IncProxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees - TradingView
Pacira BioSciences, Inc. Receives Glass Lewis Endorsement for Director Nominees Ahead of 2026 Annual Meeting - Quiver Quantitative
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote 'FOR” All of Pacira’s Director Nominees - The Manila Times
Leading Independent Proxy Advisory Firm Glass Lewis - GlobeNewswire
DOMA Perpetual Capital Provides Information to Shareholders of Pacira BioSciences - marketscreener.com
DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION - Quantisnow
Pacira study links EXPAREL to lower opioid use after surgery - Investing.com UK
Considering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the Details - Yahoo Finance
Pacira BioSciences urges shareholders to suppor... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Pacira (PCRX) Highlights Positive Study Outcomes on Exparel Usage - GuruFocus
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees - The Manila Times
Pacira BioSciences Mails Letter to Stockholders Reiterating - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Pacira BioSciences Says Exparel Linked to Lower Opioid Use, Healthcare Costs - Moomoo
Pacira study links EXPAREL to lower opioid use after surgery By Investing.com - Investing.com Australia
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty - The Manila Times
Pacira BioSciences Reports Real-World Study Showing - GlobeNewswire
Pacira (PCRX) Addresses Stockholder Concerns Over Misleading Cla - GuruFocus
Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy - The Manila Times
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):